Spelling suggestions: "subject:"[een] CONTROLLED RELEASE"" "subject:"[enn] CONTROLLED RELEASE""
1 |
Formulation of an oral acetylsalicylic acid suspension and pharmacokinetics of parenteral thrombomodulin analoguesPiepmeier, Edward H. 16 April 1991 (has links)
Sustained concentrations of active compound were maintained
in vitro and in vivo for an oral and a parenteral dosage form
respectively. The vehicle of a oral dosage form was modified and the
molecular structure of a parenteral dosage form was modified. An oral
dosage form was tested in vitro using dissolution apparatus. A
parenteral dosage form was tested in vivo using rats.
A new oral suspension dosage form for acetylsalicylic acid was
compared to two controlled release forms and two immediate release
dosage forms which are currently commercially available. A parenteral
thrombomodulin analogue conjugated to polyethylene glycol was
compared to the unconjugated thrombomodulin analogue. In each
case the goal was to maintain sustained concentrations of active
compound. / Graduation date: 1991
|
2 |
The development and assessment of both a separate, once-daily modified release matrix formulation of metoprolol tartrate and a combination formulation with hydrochlorothiazideArjun, Jessica January 2001 (has links)
The use of controlled release dosage forms has increased significantly in recent years as they result in increased patient compliance and higher therapeutic efficiency. This research focused on the development of a once daily dosage form that could be used for the treatment of hypertension. Both a separate sustained release dosage of metoprolol tartrate and a combination dosage form that included both an immediate release hydrochlorothiazide and a sustained release metoprolol component, were developed and evaluated. A matrix tablet, consisting of an ethylcellulose ranulation of metoprolol tartrate compressed into a hydrophilic hydroxypropyl methylcellulose polymer matrix, effectively sustained metoprolol release over a 22-hour experimental period. A multiparticulate combination dosage form that consisted of six coated mini matrix tablets of metoprolol and a powder blend of hydrochlorothiazide packed into a gelatin capsule, displayed zero order release kinetics for metoprolol release over 22 hours (r2=0.9946). The release of hydrochlorothiazide was found to be comparable to that of a commercially available product tested. Differential Scanning Calorimetry was used to identify possible incompatibilities between MPTA and excipients initially, and long term stability testing was used to assess to behaviour of the dosage form. Dissolution testing of the dosage forms was performed using USP Apparatus III, which was found to be more discriminating between the batches assessed. Dissolution curves were evaluated for similarity and difference using f1 and f2 fit factors. Samples were analyzed using a high performance liquid chromatographic method that was developed and validated for the simultaneous determination of the compounds of interest. Various factors influencing drug release from the developed dosage forms were assessed and recommendations for further optimization of the formulation are made. Factors evaluated included the quantity of granulating fluid, matrix polymer content, drug load and process variables, including drying time and compression force. The influence of various coating levels on drug release was assessed and none of the levels assessed were found to adequately retarded drug release over a 22-hour period. Combinations of tablets coated to different levels allowed for the successful development of a sustained release metoprolol component, which could be included into the combination dosage form.
|
3 |
Factors influencing formation and the in vitro drug release from pellets containing chitosanQuigley, Karen Josephine January 1994 (has links)
No description available.
|
4 |
Influence of process variables on the preparation of spherical granulesChapman, Stephen Robert January 1985 (has links)
No description available.
|
5 |
Development and evaluation of a sustained release amoxicillin dosage formGe, Yan, 1962- 23 August 1994 (has links)
Graduation date: 1995
|
6 |
Evaluation of gastrointestinal transit time and novel oral acetaminophen product formulationHossain, Mohammad 10 April 1991 (has links)
Gastrointestinal (GI) transit data were collected using pigs
as animal models. Density and size effects of non-disintegrating
dosage forms on GI transit were investigated. Total GI transit
times range from 2 to 33 days for 22 administrations of these nondisintegrating
dosage forms. Pigs are found to not be an
appropriate animal model for studying bioavailability or GI transit
of non-disintegrating, non-erodible oral release dosage forms.
Development of controlled release dosage forms where the
mechanism of drug release is diffusion through polymeric membrane
formed via film coating utilizing fluid-bed technology requires
optimization of several processing and formulation variables. The
influence of a processing variable (nozzle orifice opening) and a
few formulation variables (individual vs. combination plasticizer,
or a water-insoluble additive) on dissolution of a model drug
(acetaminophen) spray coated with Aquacoat® were studied.
Pharmacodynamic and pharmacokinetic information for a model
drug (acetaminophen) and computer simulation were used to develop a
dosage form with a 12 hour sustained release for oral administration
to children and adults for maximum analgesic and
antipyretic effect. Simulated plasma acetaminophen concentration-time
curves were similar to observed bioavailability study
profiles. In vitro and preliminary in vivo results from an adult
human volunteer indicate that sustained therapeutic saliva
acetaminophen concentration is possible using the newly developed
acetaminophen molded tablet dosage form.
The bioavailability of the new, oral controlled release
acetaminophen molded tablet relative to a commercially available
product (Extra-Strength Tylenol® caplet) was evaluated in 8
healthy, adult volunteers. Multiple doses of these two products
were administered in a two-way cross-over design. Bioavailability
of the new sustained release molded tablet is comparable to that of
the immediate release product. Polymer coated acetaminophen beads
were effective in maintaining saliva acetaminophen concentrations
of 5 μ/ml over a 12 hour dosing interval. / Graduation date: 1991
|
7 |
A degradable bioactive glass : an in vitro and in vivo studyCartmell, Sarah Harriet January 1999 (has links)
No description available.
|
8 |
Studies of multiple emulsions as potential prolonged release drug delivery systems /Kavaliunas, Dalia Regina January 1980 (has links)
No description available.
|
9 |
Development of novel spray coated soft elastic gelatin capsule sustained release formulations of nifedipine, bioavailability and bioequivalence of verapamil HCL controlled release formulations, pharmacokinetics of terbinafine after single oral doses in raptorsFahmy, Sahar Abd El-Sattar 08 July 2004 (has links)
This dissertation describes the development of a new sustained release
formulation of nifedipine. The new formulation was developed by coating
commercially available immediate release soft elastic gelatin capsules using a spray
coating technique with two different polymeric combinations. Dissolution studies
were conducted and showed that controlled release of nifedipine was obtained by
increasing the ratio of the water insoluble polymer in the coat and increasing the
percent weight gain of the coating. Simulated plasma concentration versus time
profiles after administration of 30 mg dose of selected formulations showed a
prolonged nifedipine release with concentrations above the minimum effective
concentration for up to 12 hours.
Bioavailability and bioequivalence of tableted test formulation of verapamil
HCL was determined in 8 volunteers and compared to Covera HS® under fed and
fasting conditions. The 90% confidence intervals for individual percent ratios of the
Cmax, AUC₀₋₅₈ and AUC₀ were not within the range of 80 - 125% in both fed fasted states, suggesting that these formulations are not bioequivalent. the bioavailability of verapamil from the new formulation was higher state but this effect was not statistically significant.
Pharmacokinetics of terbinafine administered orally at single doses of 15,
30, 60 and 120 mg were determined in raptors to recommend an appropriate dosing
scheduled for terbinafine in the treatment of Aspergillosis. Calculation of steady
state trough terbinafine plasma concentration after administration of daily doses of
15 or 30 mg/day showed that 30 mg daily dose of terbinafine administered orally
in raptors produces a steady state trough terbinafine plasma concentration above the
minimum inhibitory concentration (MIC) of(0.8 1.6) µg/ml against aspregillus
fumigatus. From the data, 30 mg per day oral dose of terbinafine should be the
recommended dose for treatment of aspergillosis in raptors. Approximate
pharmacokinetic linearity of terbinafine was demonstrated for AUC[subscript 0-t] in the dose
range of 15 120 mg while non-linearity for Cmax in the same dose range was
demonstrated using the power model. / Graduation date: 2005
|
10 |
The extrusion of various formulations of microcrystalline cellulosesRaines, Catherine Lindsay January 1990 (has links)
No description available.
|
Page generated in 0.0366 seconds